Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment

Clinical Infectious Diseases

Volumn 40, Issue 8, 2005, Pages 1194-1198

  Gallant, Joel E ^a   Parish, Michelle A ^a   Keruly, Jeanne C ^a   Moore, Richard D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ADULT; ARTICLE; COHORT ANALYSIS; CREATININE CLEARANCE; DIABETES MELLITUS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FUNCTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; TREATMENT WITHDRAWAL;

ADENINE; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CREATININE; FEMALE; HIV INFECTIONS; HUMANS; KIDNEY DISEASES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 16844370820     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/428840     Document Type: Article

References (31)

1. Benhamou Y, Bouchet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358:718-23.
2. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA 2004; 292:191-201.
3. Staszewski S, Gallant JE, Pozniak AL, et al. Three-year analysis of the renal safety of tenofovir DF (TDF) vs. stavudine (d4T) when used in combination with lamivudine (3TC) and efavirenz (EFV) in antiretroviral-naïve patients [abstract WePeB5917]. In: Program and abstracts of the XV International AIDS Conference (Bangkok). 2004.
4. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002; 40:1331-3.
5. Créput C, Gonzales-Canali G, Hill G, Piketti C, Kazatchkine M, Nochy D. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS 2003; 17:935-7.
6. Schaaf B, Aries SP, Kramme E, et al. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2003; 37:e41-3.
7. Blick G, Greiger-Zanlungo P, Garton T, Hatton E, Lopez RJ. Tenofovir may cause severe hypophosphatemia in HIV/AIDS patients with prior adefovir-induced renal tubular acidosis [abstract 717]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). 2003.
8. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36:1070-3.
9. Peyrière H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004; 35:269-73.
10. Coca S, Perazella MA. Acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci 2002; 324:342-4.
11. Gaspar G, Monereo A, Garcia-Reyne A, de Guzman M. Fanconi syndrome and acute renal failure in a patient treated with tenofovir: a call to action. AIDS 2004; 18:351-2.
12. Moore RD. Understanding the clinical and economic outcomes of HIV therapy: the Johns Hopkins HIV clinical practice cohort. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17(Suppl 1):S38-41.
13. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
14. Kearney BP, Liaw S, Yale K, et al. Pharmacokinetics following single dose administration of tenofovir DF in subjects with renal impairment [poster P4]. In: Program and abstracts of the 6th International Congress on Drug Therapy in HIV (Glasgow). 2002.
15. Viread [package insert]. Foster City, California: Gilead Sciences, 2004.
16. Squires K, Pozniak AL, Pierone G, et al. Tenofovir DF in antiretroviral-experienced, nucleoside-resistant HIV-1 infected patients with incomplete viral suppression. Ann Intern Med 2003; 139:313-20.
17. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002; 16:1257-63.
18. Izzedine H, Isnard-Bagnis C, Hulot J-S, et al. Renal safety of tenofovir in HIV-experienced patients. AIDS 2004; 18:1074-6.
19. Gallais H, Lazzarin A, Adam A, et al. The Viread Expanded Access Program (EAP) in Europe/Australia: summary of the safety and efficacy of tenofovir disoproxil fumarate (TDF) in antiretroviral treatment (ART) experience patients [abstract TuPeB4552]. In: Program and abstracts of the XV International AIDS Conference (Bangkok). 2004.
20. Jones R, Stebbing J, Nelson N, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case control study. J Acquir Immune Defic Syndr 2004; 37:1489-95.
21. Scott JD, Wolfe PR, Quiros J, Behrooznia E, Buyer B, Bolan RK. Rare occurrence of renal toxicity when retrospectively evaluating the use of tenofovir DF in 2 clinical practices [abstract uPeB4532]. In: Program and abstracts of the XV International AIDS Conference (Bangkok). 2004.
22. Lewis S, Gathe J, Ebrahimi R, Flaherty J, Wallace RJ. Comparative evaluation of renal function (RF) in HIV-infected, treatment-naive patients of African American (AA) descent receiving HAART regimens containing either tenofovir DF (TDF) or zidovudine [abstract TuPeB4599]. In: Program and abstracts of the XV International AIDS Conference (Bangkok). 2004.
23. Roca B, Gisbert C, Cabestany B, Perez AP, Ventura JM. Metabolic and renal profile before and after tenofovir DF [abstract B10708]. In: Program and abstracts of the XV International AIDS Conference (Bangkok). 2004.
24. Jaegel-Guedes E, Wolf E, Ruemmelein N, et al. Incidence of tenofovir-related nephrotoxicity in a large outpatient cohort [abstract WePeB5937]. In: Program and abstracts of the XV International AIDS Conference (Bangkok). 2004.
25. Horberg MA, Klein DB, Yu J, Sinn K, Yu J. Effect of tenofovir on renal function in a "real world" clinic setting [abstract WePpB2066]. In: Program and abstracts of the XV International AIDS Conference (Bangkok). 2004.
26. Mauss S, Berger F, Carls H, Schmutz G. Tenofovir is associated with mild renal dysfunction [abstract WePeB5941]. In: Program and abstracts of the XV International IDS Conference (Bangkok). 2004.
27. Chin-Beckford N, Kaul S, Jayaweera DT. Comorbidities drive nephrotoxicity associated with tenofovir fumarate. A case series from Florida [abstract WePeB5970]. In: Program and abstracts of the XV International AIDS Conference (Bangkok). 2004.
28. Harris M, Zalunardo N, Bonner S, Werb R, Valyi M, Montaner JSG. Use of estimated glomerular filtration rate to predict renal toxicity in patients receiving tenofovir DF [abstract 750]. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San Francisco). 2004.
29. Harris M, Zalunardo N, Yip B, et al. Nephrotoxicity of tenofovir DF [abstract 168rsqb]. In: Program and abstracts of the 12th Annual Canadian Conference on HIV/AIDS Research (Halifax). 2003.
30. Parish MA, Gallant JE, Moore RD. Changes in renal function in patients treated with tenofovir DF (TDF) vs. nucleoside reverse transcriptase inhibitors (NRTIs) [abstract 751]. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San Francisco). 2004.
31. Kearney B, Mittan A, Sayre J, et al. Pharmacokinetic drug interaction and long term safety profile of tenofovir DF and lopinavir/ritonavir [abstract A-16.17]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). 2003.